420 related articles for article (PubMed ID: 24224835)
21. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?
Bayraktar UD; Chen E; Bayraktar S; Sands LR; Marchetti F; Montero AJ; Rocha-Lima CM
Cancer; 2011 Jun; 117(11):2364-70. PubMed ID: 24048783
[TBL] [Abstract][Full Text] [Related]
22. Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database.
Bergquist JR; Thiels CA; Spindler BA; Shubert CR; Hayman AV; Kelley SR; Larson DW; Habermann EB; Pemberton JH; Mathis KL
Dis Colon Rectum; 2016 Dec; 59(12):1142-1149. PubMed ID: 27824699
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial.
Sadahiro S; Suzuki T; Ishikawa K; Yasuda S; Tajima T; Makuuchi H; Saitoh T; Murayama C
Cancer; 2004 Feb; 100(3):590-7. PubMed ID: 14745877
[TBL] [Abstract][Full Text] [Related]
24. The oncological outcome after right hemicolectomy and accuracy of CT scan as a preoperative tool for staging in right sided colonic cancers.
Lim M; Hussain Z; Howe A; Storey R; Petty D; Haselden J; Sebag-Montefiore D; Alexander D
Colorectal Dis; 2013 May; 15(5):536-43. PubMed ID: 23067005
[TBL] [Abstract][Full Text] [Related]
25. The number of high-risk factors is related to outcome in stage II colonic cancer patients.
Koebrugge B; Vogelaar FJ; Lips DJ; Pruijt JF; van der Linden JC; Ernst MF; Bosscha K
Eur J Surg Oncol; 2011 Nov; 37(11):964-70. PubMed ID: 21930361
[TBL] [Abstract][Full Text] [Related]
26. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains.
Kneuertz PJ; Chang GJ; Hu CY; Rodriguez-Bigas MA; Eng C; Vilar E; Skibber JM; Feig BW; Cormier JN; You YN
JAMA Surg; 2015 May; 150(5):402-9. PubMed ID: 25806815
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
[TBL] [Abstract][Full Text] [Related]
28. Overuse and Limited Benefit of Chemotherapy for Stage II Colon Cancer in Young Patients.
Birkett RT; Chamely E; Concors SJ; Bleier JI; Aarons CB; Shanmugan S; Saur NM; Paulson EC
Clin Colorectal Cancer; 2019 Dec; 18(4):292-300. PubMed ID: 31447135
[TBL] [Abstract][Full Text] [Related]
29. Survival and time interval from surgery to start of chemotherapy among colon cancer patients.
Zeig-Owens R; Gershman ST; Knowlton R; Jacobson JS
J Registry Manag; 2009; 36(2):30-41; quiz 61-2. PubMed ID: 19694115
[TBL] [Abstract][Full Text] [Related]
30. Opportunity lost: Adjuvant chemotherapy in patients with stage III colon cancer remains underused.
Becerra AZ; Probst CP; Tejani MA; Aquina CT; González MG; Hensley BJ; Noyes K; Monson JR; Fleming FJ
Surgery; 2015 Sep; 158(3):692-9. PubMed ID: 26032822
[TBL] [Abstract][Full Text] [Related]
31. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
32. [Benefit of adjuvant 5-fluorouracil based chemotherapy for colon cancer: a retrospective cohort study].
Mondaca S; Villalón C; Leal JL; Zúñiga Á; Bellolio F; Padilla O; Palma S; Garrido M; Nervi B
Rev Med Chil; 2016 Feb; 144(2):145-51. PubMed ID: 27092667
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study.
Hartung G; Hofheinz RD; Dencausse Y; Sturm J; Kopp-Schneider A; Dietrich G; Fackler-Schwalbe I; Bornbusch D; Gonnermann M; Wojatschek C; Lindemann W; Eschenburg H; Jost K; Edler L; Hochhaus A; Queisser W
Onkologie; 2005 Jun; 28(6-7):347-50. PubMed ID: 15933423
[TBL] [Abstract][Full Text] [Related]
34. Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer.
Cienfuegos JA; Martínez P; Baixauli J; Beorlegui C; Rosenstone S; Sola JJ; Rodríguez J; Hernández-Lizoáin JL
Ann Surg Oncol; 2017 Apr; 24(4):1077-1084. PubMed ID: 27624582
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant chemotherapy and prognostic factors in stage II colon cancer--Izmir Oncology Group Study.
Kucukzeybek Y; Dirican A; Demir L; Yildirim S; Akyol M; Yildiz Y; Bayoglu IV; Alacacioglu A; Varol U; Salman T; Yildiz I; Can H; Tarhan MO
Asian Pac J Cancer Prev; 2015; 16(6):2413-8. PubMed ID: 25824774
[TBL] [Abstract][Full Text] [Related]
36. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
Taal BG; Van Tinteren H; Zoetmulder FA;
Br J Cancer; 2001 Nov; 85(10):1437-43. PubMed ID: 11720425
[TBL] [Abstract][Full Text] [Related]
38. Early discontinuation but not the timing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: a population-based study.
Ahmed S; Ahmad I; Zhu T; Arnold FP; Faiz Anan G; Sami A; Yadav SK; Alvi R; Haider K
Dis Colon Rectum; 2010 Oct; 53(10):1432-8. PubMed ID: 20847626
[TBL] [Abstract][Full Text] [Related]
39. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
[TBL] [Abstract][Full Text] [Related]
40. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
